ABT ABBOTT LABORATORIES

NEUTRAL Impact: 4/10 8-K
Horizon weeks Filed Apr 17, 2026 Processed 1mo ago SEC 0001104659-26-044892
8-K context-dependent: Items 8.01
Latest settled — T+20d
ABT ▼ -8.49% at T+20d
NEUTRAL call ✗ call lost -8.49% · α vs SPY -12.69% · entry $96.00 → $87.85
Next anchor: T+60d in 29d
Last close $88.18 (close Jun 12) · -8.14% from $96.00 entry
Entry anchored
Apr 17, 03:59 PM ET
via Databento tick
T+1d
-3.41%
call -3.41% · α -2.75%
$92.73
settled 8w ago
T+5d
-3.30%
call -3.30% · α -4.22%
$92.83
settled 7w ago
T+20d
-8.49%
call -8.49% · α -12.69%
$87.85
settled 4w ago
T+60d
call — · α —
in 29d

Price Chart

Loading chart...

Executive Summary

Abbott Laboratories has preliminarily agreed to settle a shareholder derivative lawsuit related to its 2022 infant formula recall. The settlement includes corporate governance reforms and a potential payment of up to $15.85 million in legal fees, subject to court approval on June 4, 2026. The company denies wrongdoing but is settling to avoid further litigation costs.

Actionable Insight

The settlement resolves a lingering overhang from the 2022 formula recall, though the potential $15.85 million in legal fees represents a modest expense for a company of Abbott's size. Monitor the June 4, 2026 court hearing for final approval and any objections from shareholders. The governance reforms may lead to improved oversight, but this is unlikely to materially impact operations or financial performance.

Key Facts

  • Settlement resolves shareholder derivative litigation stemming from Abbott's 2022 infant formula recall
  • Settlement includes corporate governance reforms but no admission of wrongdoing by Abbott or its executives
  • Plaintiffs' counsel may request up to $15.85 million in attorney fees and expenses, subject to court approval
  • Final settlement hearing scheduled for June 4, 2026, before the U.S. District Court for the Northern District of Illinois
  • The company denies all allegations but is settling to eliminate the burden, expense, and uncertainty of further litigation

Financial Impact

Up to $15.85 million for legal fees and expenses, with no direct payment to the company as this is a derivative action

legal expensesoperating expenses

Risk Factors

  • Court may not approve the settlement, leading to continued litigation
  • Shareholder objections could delay or modify the settlement terms
  • Reputational risk from the underlying allegations related to the 2022 formula recall

Market Snapshot

Price
$96.89
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
74% bullish (35 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-044892
Document: tm2611915d1_8k.htm0001104659-26-044892
Document: 0001104659-26-044892-index-headers.html0001104659-26-044892
Document: 0001104659-26-044892-index.html0001104659-26-044892
Document: 0001104659-26-044892.txt0001104659-26-044892
12 reports for ABT
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+20▲ +12.20%Apr 16, 2026
Filters
Rows
Reports for ABT — sortable, filterable
Type Now
May 31, 2026
14d ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$106.00 $109.09▲ +2.92%▲ +5.28%$88.18 (−16.81%)
May 28, 2026
18d ago
Court Ruling
NEUTRAL ★ 1/10
$86.24 $86.99▲ +0.87%▲ +0.92%$88.18 (+2.25%)
May 1, 2026
6w ago
ANALYST-UPGRADE
MIXED ★ 4/10
$106.00 $109.09▲ +2.92%▲ +5.28%$88.18 (−16.81%)
Apr 27, 2026
6w ago
8-K
NEUTRAL ★ 2/10
$93.83 $87.54▼ −6.70%▼ −8.39%$88.18 (−6.02%)
Apr 23, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$91.35 $86.22▼ −5.62%▼ −8.73%$88.18 (−3.47%)
Apr 22, 2026
7w ago
Court Ruling
NEUTRAL ★ 4/10
$93.16 awaiting T+5awaiting T+5$88.18 (−5.35%)
Apr 17, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$96.00 $92.83▼ −3.30%▼ −4.22%$88.18 (−8.14%)
Apr 16, 2026
8w ago
8-K
BEARISH ★ 8/10
$95.48 $92.43▲ +3.19%▲ +4.18%$88.18 (+7.64%)
Mar 30, 2026
11w ago
Court Ruling
NEUTRAL ★ 3/10
$101.86 $101.79▼ −0.07%▼ −4.37%$88.18 (−13.43%)
Mar 23, 2026
11w ago
8-K
BULLISH ★ 8/10
$104.84 $101.86▼ −2.84%▲ +0.72%$88.18 (−15.89%)
Showing 10 of 12

US Market Status

Market Closed — Opens in 5h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access